Rocket Pharmaceuticals (RCKT) Restructuring Costs (2025)
Rocket Pharmaceuticals (RCKT) posted Restructuring Costs of -$68000.0 for Q4 2025, up 60.47% sequentially from -$172000.0 in Q3 2025.
Powered by 
Analysis
Rocket Pharmaceuticals (RCKT) Restructuring Costs (2025) Analysis & Trends
Rocket Pharmaceuticals has reported Restructuring Costs for 1 years, with the latest figure at -$68000.0 in Q4 2025.
- Quarterly Restructuring Costs changed N/A year-over-year to -$68000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.2 million (changed N/A YoY) and the FY2025 annual result came in at $3.2 million, changed N/A from the prior year.
- Restructuring Costs improved to -$68000.0 in Q4 2025 per RCKT's latest filing, from -$172000.0 in the prior quarter.
- Over five years, Restructuring Costs peaked at $3.5 million in Q2 2025 and troughed at -$172000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Rocket Pharmaceuticals | 437.27 Mn | 437.27 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -68,000.00 |
| Sep 30, 2025 | -172,000.00 |
| Jun 30, 2025 | 3.50 Mn |